Vikram D. Kodibagkar1,2, Praveen Kumar Gulaka1, Federico Rojas-Quijano3, Zoltan Kovacs3, Ralph P. Mason, 12, A Dean Sherry2,3
1Biomedical Engineering, UT Arlington and UT Southwestern Medical Center at Dallas, Dallas, Tx, United States; 2Radiology, UT Southwestern Medical Center at Dallas; 3Advanced Imaging Research Center, UT Southwestern Medical Center at Dallas, Dallas, Tx
Heterogeneously distributed hypoxic cores in tumors are known to affect radiation sensitivity and promote development of metastases, therefore the ability to image tumor hypoxia in vivo will provide useful prognostic information. Previous research demonstrated that 2-nitroimidazole accumulated in hypoxic tissues due to an enzyme mediated reduction of the nitro group in hypoxic conditions. Here we report the in vitro and in vivo evaluation of a GdDOTA monoamide conjugate of 2-nitroimidazole, GdDO3NI, as a novel hypoxia targeting MRI T1 contrast agent.